Group 1: drugs involved in clinical cholestasis | | | | | | |
BOS | Dilatation | ++a,b,c,d | 64.24 ± 4.13** | 0.10 ± 0.01*** | Dephosphorylation | MLCK |
CPZ | Constriction | +a,c,d | 49.96 ± 5.14* | 0.5 ± 0.2* | Phosphorylation | ROCK |
CsA | Constriction | ++a,b,c,d | 13.16 ± 1.48** | 0.54 ± 0.15** | Phosphorylation | ROCK |
NEF | Constriction | ++a,b,c,d | 52.46 ± 3.87*** | 0.28 ± 0.08* | Phosphorylation | ROCK |
TRO | Constriction | ++a,b,c,d | 21.97 ± 3.72*** | 0.58 ± 0.11* | Phosphorylation | ROCK |
Group 2: drugs involved in rare cases of clinical cholestasis | | | | | | |
CIM | Dilatation | +a | 86.25 ± 12.12 | 0.33 ± 0.04*** | Dephosphorylation | MLCK |
DIC | Dilatation | +a,d | 384.8 ± 57.96** | 0.66 ± 0.1* | Dephosphorylation | MLCK |
ENT | Dilatation | −b,d | 109.2 ± 16.94 | 0.83 ± 0.18 | Dephosphorylation | MLCK |
MET | Constriction | −a,d | 99.41 ± 8.45 | 0.30 ± 0.06*** | Phosphorylation | ROCK |
PER | Constriction | −d | 41.43 ± 8.22** | 0.45 ± 0.09* | Phosphorylation | ROCK |
TAC | Dilatation | −b | 56.14 ± 2.71*** | 0.44 ± 0.11** | Dephosphorylation | MLCK |
TOL | Dilatation then constriction | +b,c,d | 48.36 ± 8.14** | 0.20 ± 0.04*** | No change | MLCK - ROCK |
Group 3: drugs not involved in clinical cholestasis | | | | | | |
AMI | No change | +a,b,d | 115.6 ± 15.62 | 1.34 ± 0.19 | No change | — |
APAP | No change | −c,d | 137.2 ± 24.33 | 0.63 ± 0.14 | No change | — |
BUS | No change | −a,c,d | 86.07 ± 13.39 | 0.32 ± 0.03** | No change | — |
FIA | No change | −d | 91.34 ± 9.14 | 0.66 ± 0.08 | No change | — |
PIO | No change | +a,b,c,d | 86.15 ± 3.34 | 0.66 ± 0.08 | No change | — |
XIM | No change | −d | 96.71 ± 10.91 | 1.19 ± 0.16 | No change | — |